Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Non-randomized, First in Human (FIH) Clinical Study to Assess the Feasibility of the Novel Xeltis Coronary Artery Bypass Graft (XABG)

NCT04545112 is registered in ClinicalTrials.gov with Xeltis as lead sponsor.

NCT NCT04545112
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04545112 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Non-randomized, First in Human (FIH) Clinical Study to Assess the Feasibility of the Novel Xeltis Coronary Artery Bypass Graft (XABG)
Lead sponsor
Xeltis
Phase
Not applicable
Overall status
Enrolling by invitation
Start date
October 22, 2020
Completion date
December 31, 2031
Enrollment
20 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

multi vessel coronary artery disease